148 related articles for article (PubMed ID: 11036954)
21. The relationship of the metabolism of anticancer agents to their activity.
Montgomery JA; Struck RF
Prog Drug Res; 1973; 17():320-409. PubMed ID: 4150245
[No Abstract] [Full Text] [Related]
22. Antitumor effects of fotemustine and busulfan against a human neuroblastoma xenograft.
Ikeda H; Tsuchida Y; Wu J; Suzuki N; Kuroiwa M; Choi SH; Morikawa A
Oncol Rep; 2000; 7(6):1265-8. PubMed ID: 11032927
[TBL] [Abstract][Full Text] [Related]
23. Spin-labeled 1-alkyl-1-nitrosourea synergists of antitumor antibiotics.
Gadjeva V; Koldamova R
Anticancer Drug Des; 2001; 16(4-5):247-53. PubMed ID: 12049483
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacological aspects in the development of liposomal medicinal preparations for the internal injection of hydrophobic cytostatics].
Oborotova NA; Smirnova ZS; Polozkova ZS; Baryshnikov AIu
Vestn Ross Akad Med Nauk; 2002; (1):42-5. PubMed ID: 11882971
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacokinetics and administration of established platinum drugs.
O'Dwyer PJ; Stevenson JP; Johnson SW
Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic and antitumor activity of MEN 10710, a novel alkylating derivative of distamycin.
Bigioni M; Salvatore C; Palma C; Manzini S; Animati F; Lombardi P; Pratesi G; Supino R; Zunino F
Anticancer Drugs; 1997 Oct; 8(9):845-52. PubMed ID: 9402311
[TBL] [Abstract][Full Text] [Related]
27. Clinical applications of quinone-containing alkylating agents.
Begleiter A
Front Biosci; 2000 Nov; 5():E153-71. PubMed ID: 11056078
[TBL] [Abstract][Full Text] [Related]
28. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
29. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.
Rachid Z; Brahimi F; Qiu Q; Williams C; Hartley JM; Hartley JA; Jean-Claude BJ
J Med Chem; 2007 May; 50(11):2605-8. PubMed ID: 17472358
[TBL] [Abstract][Full Text] [Related]
30. Triazenes: a versatile tool in organic synthesis.
Kimball DB; Haley MM
Angew Chem Int Ed Engl; 2002 Sep; 41(18):3338-51. PubMed ID: 12298030
[TBL] [Abstract][Full Text] [Related]
31. Relative mutagenicity of antineoplastic drugs and other alkylating agents in V79 Chinese hamster cells, independence of cytotoxic and mutagenic responses.
Suter W; Brennand J; McMillan S; Fox M
Mutat Res; 1980 Nov; 73(1):171-81. PubMed ID: 6265771
[TBL] [Abstract][Full Text] [Related]
32. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury.
Hedley D; Ogilvie L; Springer C
Nat Rev Cancer; 2007 Nov; 7(11):870-9. PubMed ID: 17943135
[TBL] [Abstract][Full Text] [Related]
33. [Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow osteosarcoma induced in mice: a mathematical model].
Clairambault J; Claude D; Filipski E; Granda T; Lévi F
Pathol Biol (Paris); 2003 Jun; 51(4):212-5. PubMed ID: 12852993
[TBL] [Abstract][Full Text] [Related]
34. Melphalan hydrochloride for the treatment of multiple myeloma.
Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
[TBL] [Abstract][Full Text] [Related]
35. Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
Petrović IM; Korićanac LB; Todorović DV; Ristić-Fira AM; Valastro LM; Privitera G; Cuttone G
Ann N Y Acad Sci; 2007 Jan; 1095():154-64. PubMed ID: 17404028
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and preliminary cytotoxicity of nitrogen mustard derivatives of distamycin A.
Wang Y; Wright SC; Larrick JW
Bioorg Med Chem Lett; 2003 Feb; 13(3):459-61. PubMed ID: 12565950
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and DNA cleavage activity of Bis-3-chloropiperidines as alkylating agents.
Zuravka I; Roesmann R; Sosic A; Wende W; Pingoud A; Gatto B; Göttlich R
ChemMedChem; 2014 Sep; 9(9):2178-85. PubMed ID: 24616300
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
